BBA Clinical Diagnostic Lab Test Negotiated Rulemaking To Begin July 13
This article was originally published in The Gray Sheet
Clinical diagnostic laboratory tests whose medical utility or clinical effectiveness is considered "controversial" will be among the specific types of tests for which national coverage policies are to be developed through negotiated rulemaking, the Health Care Financing Administration says in a June 3 Federal Register notice.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.